Changes in HbA1c from baseline to end of treatment were -0.36 , -0.62 , and -0.75 % in the 0.5 , 2.5 , and 5mg luseogliflozin groups , respectively , versus +0.06 % in the placebo group ( all P < 0.001 ) .